PNTG · Insider Trading
The Pennant Group, Inc. Common Stock
Every open-market purchase and sale reported by PNTG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Stephen M R Covey | Director | A | +1,900 | — |
| 2026-10-19 | Barry M Smith | Director | A | +1,900 | — |
| 2026-10-19 | Scott E Lamb | Director | A | +2,400 | — |
| 2026-10-19 | John G. Nackel | Director | A | +1,900 | — |
| 2026-10-19 | Christopher R. Christensen | Director | A | +1,900 | — |
| 2026-10-19 | Gregory K Morris Sr. | Director | A | +1,900 | — |
| 2026-10-19 | Suzanne D. Snapper | Director | A | +1,900 | — |
| 2026-08-10 | Kirk Sterling Cheney | EVP, GC and Corp Secy | Sell | −1,393 | −$53.66K |
| 2026-08-10 | Brent Guerisoli | Chief Executive Officer | Sell | −4,285 | −$165.07K |
| 2026-08-10 | Jason Paul Steik | Chief Clinical Officer | Sell | −1,394 | −$53.70K |
| 2026-07-17 | Suzanne D. Snapper | Director | A | +1,900 | — |
| 2026-07-17 | Stephen M R Covey | Director | A | +1,900 | — |
| 2026-07-17 | Barry M Smith | Director | A | +1,900 | — |
| 2026-07-17 | Scott E Lamb | Director | A | +2,400 | — |
| 2026-07-17 | Gregory K Morris Sr. | Director | A | +1,900 | — |
| 2026-07-17 | John G. Nackel | Director | A | +1,900 | — |
| 2026-07-17 | Christopher R. Christensen | Director | A | +1,900 | — |
| 2026-07-14 | Brent Guerisoli | Chief Executive Officer | MIXED | +3,089 | −$102.94K |
| 2026-07-09 | Brent Guerisoli | Chief Executive Officer | MIXED | +3,084 | −$99.84K |
| 2026-05-27 | Brent Guerisoli | Chief Executive Officer | MIXED | +4,418 | −$123.86K |
| 2026-04-17 | Suzanne D. Snapper | Director | A | +1,900 | — |
| 2026-04-17 | Barry M Smith | Director | A | +1,900 | — |
| 2026-04-17 | John J Gochnour | Chief Operating Officer | A | +11,214 | — |
| 2026-04-17 | Scott E Lamb | Director | A | +2,400 | — |
| 2026-04-17 | Brent Guerisoli | Chief Executive Officer | A | +11,260 | — |
| 2026-04-17 | Stephen M R Covey | Director | A | +1,900 | — |
| 2026-04-17 | John G. Nackel | Director | A | +1,900 | — |
| 2026-04-17 | Kirk Sterling Cheney | EVP, GC and Corp Secy | A | +2,874 | — |
| 2026-04-17 | Gregory K Morris Sr. | Director | A | +1,900 | — |
| 2026-04-17 | Lynette Walbom | Chief Financial Officer | A | +8,025 | — |
| 2026-04-17 | Christopher R. Christensen | Director | A | +1,900 | — |
| 2026-03-12 | Kirk Sterling Cheney | EVP, GC and Corp Secy | A | +4,085 | — |
| 2026-03-12 | Jason Paul Steik | Chief Clinical Officer | A | +26,000 deriv. | — |
| 2026-03-12 | Lynette Walbom | Chief Financial Officer | A | +14,292 | — |
| 2026-03-12 | Brent Guerisoli | Chief Executive Officer | A | +20,052 | — |
| 2026-03-12 | John J Gochnour | Chief Operating Officer | A | +18,565 | — |
| 2026-01-21 | Scott E Lamb | Director | A | +2,400 | — |
| 2026-01-21 | Suzanne D. Snapper | Director | A | +1,900 | — |
| 2026-01-21 | Gregory K Morris Sr. | Director | A | +1,900 | — |
| 2026-01-21 | Stephen M R Covey | Director | A | +1,900 | — |
| 2026-01-21 | John G. Nackel | Director | A | +1,900 | — |
| 2026-01-21 | Christopher R. Christensen | Director | A | +1,900 | — |
| 2026-01-21 | Barry M Smith | Director | A | +1,900 | — |
| 2025-11-13 | Kirk Sterling Cheney | EVP, GC and Corp Secy | M | +3,800 | +$57.34K |
| 2025-10-16 | Scott E Lamb | Director | A | +2,400 | — |
| 2025-10-16 | John G. Nackel | Director | A | +1,900 | — |
| 2025-10-16 | Christopher R. Christensen | Director | A | +1,900 | — |
| 2025-10-16 | Gregory K Morris Sr. | Director | A | +1,900 | — |
| 2025-10-16 | Barry M Smith | Director | A | +1,900 | — |
| 2025-10-16 | Stephen M R Covey | Director | A | +1,900 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Christopher R. Christensen | Director | 771,238 | $31.65M |
| Suzanne D. Snapper | Director | 232,264 | $9.53M |
| John G. Nackel | Director | 179,165 | $7.35M |
| John J Gochnour | Chief Operating Officer | 145,464 | $5.97M |
| Barry M Smith | Director | 104,399 | $4.28M |
| Brent Guerisoli | Chief Executive Officer | 99,544 | $4.09M |
| Scott E Lamb | Director | 61,335 | $2.52M |
| Stephen M R Covey | Director | 45,950 | $1.89M |
| Gregory K Morris Sr. | Director | 39,200 | $1.61M |
| JoAnne Stringfield | Director | 30,275 | $1.24M |
| Kirk Sterling Cheney | EVP, GC and Corp Secy | 18,401 | $755.18K |
| Jason Paul Steik | Chief Clinical Officer | 15,106 | $619.95K |
| Lynette Walbom | Chief Financial Officer | 10,688 | $438.64K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PNTG quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.